|Bid||0.00 x 800|
|Ask||0.00 x 4000|
|Day's Range||2.90 - 3.01|
|52 Week Range||2.58 - 5.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.58|
Achillion Pharmaceuticals, Inc. (ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 9:00 a.m. ET at the St. Regis New York Hotel, in New York, NY. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation.
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK ...
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).
Achillion Pharmaceuticals, Inc. (ACHN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Barclays revised its view of several smaller mid-cap biotech stocks after the first-quarter earnings season, issuing re-ratings Monday for Prothena Corporation PLC (NASDAQ: PRTA ) and Achillion Pharmaceuticals, ...
Some M&A activity , earnings news flow and clinical trial outcomes helped the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) preserve gains this week. As the earnings season winds down, here're ...
Achillion Pharmaceuticals, Inc. (ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway for orphan diseases, today announced that two abstracts were accepted for presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress being hosted in Copenhagen, Denmark from May 24 – 27, 2018. Abstracts can be accessed on the ERA-EDTA website at http://www.era-edta2018.org/en-US/home.Reprints of the oral and poster presentations will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Esperion Therapeutics, Inc. (NASDAQ: ESPR) all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ESPR as the Company's latest news hit the wire. On May 2, 2018, the Company announced positive top-line results from the second pivotal, Phase-3 study (Study 1/1002-040) the long-term safety study, evaluating the safety, tolerability, and efficacy of bempedoic acid versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statin therapy. Active-Investors.com is currently working on the research report for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), which also belongs to the Healthcare sector as the Company Esperion Therapeutics.
Achillion Pharmaceuticals, Inc. (ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at 9:20 a.m. ET at the Intercontinental Boston Hotel, Boston, MA. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com.
Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.
The New Haven, Connecticut-based company said it had a loss of 15 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Achillion Pharmaceuticals, Inc. (ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway, today reported financial results for the three months ended March 31, 2018. For the first quarter of 2018, the Company reported a net loss of $20.6 million or $0.15 per share, compared with a net loss of $20.2 million or $0.15 per share for the first quarter of 2017. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2018 were $308.4 million.
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Investors in Achillion Pharmaceuticals (ACHN) need to pay close attention to the stock based on moves in the options market lately.
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]
Investing in cheap stocks can be risky and inexperienced investors are usually advised to stay clear of them, even though many new investors go straight to cheap stocks hoping to score big. Of course, in case of a successful investment, the returns can indeed be very big, given that cheap stocks are prone to bigger […]
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares rise more than 15% on the day.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / U.S. markets rose for the third consecutive session on Monday on the strength of technology shares. The Dow Jones Industrial Average spiked 1.58 percent ...
Stock Monitor: Achillion Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Bellicum Pharma, Inc. (NASDAQ: BLCM ...